Vivos Therapeutics, a medical device company, closed the exercise of outstanding warrants, raising $4.64 million in gross proceeds. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. In exchange for the exercise of warrants, the company issued new unregistered warrants for the purchase of up to 3,964,712 shares of common stock. Vivos plans to use the net proceeds for working capital and general corporate purposes. The new warrants are part of a private placement and were offered under an exemption from registration requirements. Vivos is focused on developing innovative diagnostic and treatment methods for breathing and sleep disorders related to obstructive sleep apnea.

Read more at GlobeNewswire: Vivos Therapeutics Announces Closing of Exercise of